{"article_title": "Overheard: Keryx\u2019s Value in Profits", "article_keywords": ["treating", "used", "returned", "keryxs", "auryxia", "results", "value", "start", "overheard", "keryx", "drug", "seen", "sept", "profits"], "article_url": "http://www.wsj.com/articles/overheard-keryxs-value-in-profits-1425242393", "article_text": "Getting a drug approved for commercial use is difficult. For biotech companies, that isn\u2019t the full extent of the challenge.\n\nThis can be seen in fourth-quarter results of Keryx Biopharmaceuticals, which makes a phosphate binder used in treating chronic kidney disease. Its drug, Auryxia, generated great excitement. From the start of 2013 through the Food and Drug Administration\u2019s approval of Auryxia on Sept. 5, 2014, Keryx returned...", "article_metadata": {"article.template": "snippet", "article.created": "2015-03-01T20:39:00.000Z", "article.section": "Markets", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Overheard: Keryx\u2019s Value in Profits", "title": "Overheard: Keryx\u2019s Value in Profits", "image": {"alt": "Overheard: Keryx\u2019s value in profits", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB12729948149543524457504580488333683764868&headline=Overheard%3A%20Keryx%u2019s%20value%20in%20profits&weburl=http://www.wsj.com/articles/SB12729948149543524457504580488333683764868"}}, "page.site.product": "WSJ", "keywords": "Keryx Biopharmaceuticals,KERX,financial performance,earnings,corporate,industrial news,biotechnology,political,general news,sciences,technologies,commodity,financial market news,analyses,pharmaceuticals,health care,life sciences,biopharmaceuticals,drugs,medication", "news_keywords": "Keryx Biopharmaceuticals,KERX,financial performance,earnings,corporate,industrial news,biotechnology,political,general news,sciences", "article.headline": "Overheard: Keryx\u2019s value in profits", "description": "Overheard: Keryx\u2019s Value in Profits", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB12729948149543524457504580488333683764868&headline=Overheard%3A%20Keryx%u2019s%20value%20in%20profits&weburl=http://www.wsj.com/articles/SB12729948149543524457504580488333683764868", "user.type": "nonsubscriber", "article.page": "Heard on the Street", "page.content.format": "responsive", "article.summary": "Overheard: Keryx\u2019s Value in Profits", "page.site": "wsj", "testkeys": "A", "article.published": "2015-03-01T20:39:00.000Z", "dj.asn": "i-4bdc", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "word_count": 173}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Overheard: Keryx\u2019s Value in Profits", "title": "Overheard: Keryx\u2019s Value in Profits", "url": "http://www.wsj.com/articles/overheard-keryxs-value-in-profits-1425242393", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Overheard: Keryx\u2019s Value in Profits", "article.type": "Heard on the Street Other", "article.id": "SB12729948149543524457504580488333683764868", "user.exp": "default", "article.updated": "2015-03-01T20:39:00.000Z"}, "article_summary": "From the start of 2013 through the Food and Drug Administration\u2019s approval of Auryxia on Sept. 5, 2014, Keryx returned...\nIts drug, Auryxia, generated great excitement.\nThis can be seen in fourth-quarter results of Keryx Biopharmaceuticals, which makes a phosphate binder used in treating chronic kidney disease.\nGetting a drug approved for commercial use is difficult.\nFor biotech companies, that isn\u2019t the full extent of the challenge."}